Effects of Metformin Hydrochloride combined with Insulin Aspartate on Serum SF, RBP4, Hcy and Cys-C in Pregnant Women with Gestational Diabetes Mellitus

  • Lin Wang
Keywords: Metformin hydrochloride; Insulin aspartate; Gestational diabetes mellitus; SF; RBP4; Hcy; Cys-C

Abstract

This paper analyze the effects of metformin hydrochloride combined with insulin aspartate on serum ferritin (SF), retinol binding protein (RBP4), homocysteine (Hcy) and cystatin C (Cys-C) in pregnant women with gestational diabetes mellitus (GDM). The clinical efficacy, blood glucose level (FPG), 1 hour postprandial blood glucose (1hPG), 2 hours postprandial blood glucose (2hPG), glycosylated hemoglobin Alc (HbAlc), serum SF, RBP4, Hcy, Cys-C levels, adverse reactions and neonatal conditions were compared between the two groups. After treatment, the total effective rate was 95.74% in the treatment group, which was significantly higher than 80.85% in the control group (P < 0.05). Before treatment, there was no significant difference in FPG, 1hPG, 2hPG and HbAlc levels between the two groups (P > 0.05). After treatment, the blood sugar indexes of the two groups decreased significantly, and the treatment group was significantly lower than the control group (P < 0.05). The serum levels of SF, RBP4, Hcy and Cys-C in the two groups decreased after treatment, and the above indexes in the treatment group were significantly lower than those in the control group, with statistical significance (P < 0.05). The incidence of adverse reactions in the treatment group was 12.77%, which was significantly lower than that in the control group (42.55% (P < 0.01). Metformin hydrochloride combined with insulin aspartate in the treatment of GDM patients has significant efficacy, high safety, and obvious effect on blood sugar control. It can effectively reduce the serum SF, RBP4, Hcy, Cys-C levels in pregnant women with GDM and improve maternal and infant outcomes.

Published
2020-01-01